Mvasi

Last reviewed on RxList: 4/29/2021
Mvasi Side Effects Center

What Is Mvasi?

Mvasi (bevacizumab-awwb) Solution is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment; for metastatic colorectal cancer, with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen; for non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; for glioblastoma, as a single agent for adult patients with progressive disease following prior therapy; for metastatic renal cell carcinoma with interferon alfa; and for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

What Are Side Effects of Mvasi?

Common side effects Mvasi include:

Dosage for Mvasi

The dosage and administration of Mvasi Solution depends on the condition being treated.

What Drugs, Substances, or Supplements Interact with Mvasi?

Mvasi may interact with other drugs. Tell your doctor all medications and supplements you use.

Mvasi During Pregnancy or Breastfeeding

Mvasi Solution is not recommended for use during pregnancy; it may harm a fetus. Women are advised to use effective contraception during treatment with Mvasi and for 6 months after the last dose of Mvasi. It is unknown if Mvasi passes into breast milk. Because of the potential for adverse reactions in nursing infants, use of Mvasi is not recommended while breastfeeding.

Additional Information

Our Mvasi (bevacizumab-awwb) Solution for Intravenous Infusion Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

What are risk factors for developing colon cancer? See Answer
Mvasi Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, light-headed, short of breath, chilled, sweaty, or have a headache, chest pain, wheezing, or swelling in your face.

Bevacizumab can make it easier for you to bleed. Call your doctor or seek emergency medical attention if you have:

  • easy bruising, unusual bleeding (nose, mouth, vagina, rectum), or any bleeding that will not stop;
  • signs of bleeding in your digestive tract--severe stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or
  • signs of bleeding in the brain--sudden numbness or weakness (especially on one side of the body), sudden severe headache, problems with vision or balance.

Bevacizumab can cause a rare but serious neurologic disorder affecting the brain. Symptoms may occur within hours of your first dose, or they may not appear for up to a year after your treatment started. Call your doctor at once if you have extreme weakness or tiredness, headache, confusion, vision problems, fainting, or seizure (blackout or convulsions).

Some people receiving bevacizumab have developed a fistula (an abnormal passageway) within the throat, lungs, gallbladder, kidney, bladder, or vagina. Call your doctor if you have: chest pain and trouble breathing, stomach pain or swelling, urine leakage, or if you feel like you are choking and gagging when you eat or drink.

Also call your doctor if you have:

  • pain, swelling, warmth, or redness in one or both legs;
  • chest pain or pressure, pain spreading to your jaw or shoulder;
  • missed menstrual periods;
  • kidney problems--puffy eyes, swelling in your ankles or feet, urine that looks foamy;
  • heart problems--swelling, rapid weight gain, feeling short of breath;
  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing;
  • signs of any skin infection--sudden redness, warmth, swelling, or oozing, or any skin wound or surgical incision that will not heal; or
  • increased blood pressure--severe headache, blurred vision, pounding in your neck or ears.

Side effects may be more likely in older adults.

Common side effects may include:

  • nosebleed, rectal bleeding;
  • increased blood pressure;
  • headache, back pain;
  • dry or watery eyes;
  • dry or flaky skin;
  • runny nose, sneezing; or
  • changes in your sense of taste.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion)

SLIDESHOW

Digestive Disorders: Common Misconceptions See Slideshow
Mvasi Professional Information

SIDE EFFECTS

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Gastrointestinal Perforations and Fistulae [see WARNINGS AND PRECAUTIONS].
  • Surgery and Wound Healing Complications [see WARNINGS AND PRECAUTIONS].
  • Hemorrhage [see WARNINGS AND PRECAUTIONS].
  • Arterial Thromboembolic Events [see WARNINGS AND PRECAUTIONS].
  • Venous Thromboembolic Events [see WARNINGS AND PRECAUTIONS].
  • Hypertension [see WARNINGS AND PRECAUTIONS].
  • Posterior Reversible Encephalopathy Syndrome [see WARNINGS AND PRECAUTIONS].
  • Renal Injury and Proteinuria [see WARNINGS AND PRECAUTIONS].
  • Infusion-Related Reactions [see WARNINGS AND PRECAUTIONS].
  • Ovarian Failure [see WARNINGS AND PRECAUTIONS].
  • Congestive Heart Failure [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The safety data in Warnings and Precautions and described below reflect exposure to bevacizumab in 4134 patients including those with mCRC (AVF2107g, E3200), non-squamous NSCLC (E4599), GBM (EORTC 26101), mRCC (BO17705), and cervical cancer (GOG-0240), including controlled studies or other cancers, at the recommended dose and schedule for a median of 6 to 23 doses. The most common adverse reactions observed in patients receiving bevacizumab as a single agent or in combination with chemotherapy at a rate > 10% were epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.

Across clinical studies, bevacizumab was discontinued in 8% to 22% of patients because of adverse reactions [see Clinical Studies].

Metastatic Colorectal Cancer

In Combination with bolus-IFL

The safety of bevacizumab was evaluated in 392 patients who received at least one dose of bevacizumab in a double-blind, active-controlled study (AVF2107g), which compared bevacizumab (5 mg/kg every 2 weeks) with bolus-IFL to placebo with bolus-IFL in patients with mCRC [see Clinical Studies]. Patients were randomized (1:1:1) to placebo with bolus-IFL, bevacizumab with bolus-IFL, or bevacizumab with fluorouracil and leucovorin. The demographics of the safety population were similar to the demographics of the efficacy population. All Grades 3−4 adverse reactions and selected Grades 1−2 adverse reactions (i.e., hypertension, proteinuria, thromboembolic events) were collected in the entire study population. Adverse reactions are presented in Table 2.

Table 2: Grades 3-4 Adverse Reactions Occurring at Higher Incidence (≥ 2%) in Patients Receiving Bevacizumab vs. Placebo in Study AVF2107g

Adverse Reactiona Bevacizumab with IFL
(N = 392)
Placebo with IFL
(N = 396)
Hematology    
  Leukopenia 37% 31%
  Neutropenia 21% 14%
Gastrointestinal    
  Diarrhea 34% 25%
  Abdominal pain 8% 5%
  Constipation 4% 2%
Vascular    
  Hypertension 12% 2%
  Deep vein thrombosis 9% 5%
  Intra-abdominal Thrombosis 3% 1%
  Syncope 3% 1%
General    
  Asthenia 10% 7%
  Pain 8% 5%
a NCI-CTC version 3.

In Combination with FOLFOX4

The safety of bevacizumab was evaluated in 521 patients in an open-label, active-controlled study (E3200) in patients who were previously treated with irinotecan and fluorouracil for initial therapy for mCRC. Patients were randomized (1:1:1) to FOLFOX4, bevacizumab (10 mg/kg every 2 weeks prior to FOLFOX4 on Day 1) with FOLFOX4, or bevacizumab alone (10 mg/kg every 2 weeks). Bevacizumab was continued until disease progression or unacceptable toxicity.

The demographics of the safety population were similar to the demographics of the efficacy population.

Selected Grades 3−5 non-hematologic and Grades 4−5 hematologic occurring at a higher incidence (≥ 2%) in patients receiving bevacizumab with FOLFOX4 compared to FOLFOX4 alone were fatigue (19% vs. 13%), diarrhea (18% vs. 13%), sensory neuropathy (17% vs. 9%), nausea (12% vs. 5%), vomiting (11% vs. 4%), dehydration (10% vs. 5%), hypertension (9% vs. 2%), abdominal pain (8% vs. 5%), hemorrhage (5% vs. 1%), other neurological (5% vs. 3%), ileus (4% vs. 1%) and headache (3% vs. 0%). These data are likely to under-estimate the true adverse reaction rates due to the reporting mechanisms.

First-Line Non-Squamous Non-Small Cell Lung Cancer

The safety of bevacizumab was evaluated as first-line treatment in 422 patients with unresectable NSCLC who received at least one dose of bevacizumab in an active-controlled, open-label, multicenter trial (E4599) [see Clinical Studies]. Chemotherapy-naïve patients with locally advanced, metastatic or recurrent non–squamous NSCLC were randomized (1:1) to receive six 21-day cycles of paclitaxel and carboplatin with or without bevacizumab (15 mg/kg every 3 weeks). After completion or upon discontinuation of chemotherapy, patients randomized to receive bevacizumab continued to receive bevacizumab alone until disease progression or until unacceptable toxicity. The trial excluded patients with predominant squamous histology (mixed cell type tumors only), CNS metastasis, gross hemoptysis (1/2 teaspoon or more of red blood), unstable angina, or receiving therapeutic anticoagulation. The demographics of the safety population were similar to the demographics of the efficacy population.

Only Grades 3-5 non-hematologic and Grades 4-5 hematologic adverse reactions were collected. Grades 3-5 non-hematologic and Grades 4-5 hematologic adverse reactions occurring at a higher incidence (≥ 2%) in patients receiving bevacizumab with paclitaxel and carboplatin compared with patients receiving chemotherapy alone were neutropenia (27% vs. 17%), fatigue (16% vs. 13%), hypertension (8% vs. 0.7%), infection without neutropenia (7% vs. 3%), venous thromboembolism (5% vs. 3%), febrile neutropenia (5% vs. 2%), pneumonitis/pulmonary infiltrates (5% vs. 3%), infection with Grade 3 or 4 neutropenia (4% vs. 2%), hyponatremia (4% vs. 1%), headache (3% vs. 1%) and proteinuria (3% vs. 0%).

Recurrent Glioblastoma

The safety of bevacizumab was evaluated in a multicenter, randomized, open-label study (EORTC 26101) in patients with recurrent GBM following radiotherapy and temozolomide of whom 278 patients received at least one dose of bevacizumab and are considered safety evaluable [see Clinical Studies]. Patients were randomized (2:1) to receive bevacizumab (10 mg/kg every 2 weeks) with lomustine or lomustine alone until disease progression or unacceptable toxicity. The demographics of the safety population were similar to the demographics of the efficacy population. In the bevacizumab with lomustine arm, 22% of patients discontinued treatment due to adverse reactions compared with 10% of patients in the lomustine arm. In patients receiving bevacizumab with lomustine, the adverse reaction profile was similar to that observed in other approved indications.

Metastatic Renal Cell Carcinoma

The safety of bevacizumab was evaluated in 337 patients who received at least one dose of bevacizumab in a multicenter, double-blind study (BO17705) in patients with mRCC. Patients who had undergone a nephrectomy were randomized (1:1) to receive either bevacizumab (10 mg/kg every 2 weeks) or placebo with interferon-alfa [see Clinical Studies]. Patients were treated until disease progression or unacceptable toxicity. The demographics of the safety population were similar to the demographics of the efficacy population.

Grades 3-5 adverse reactions occurring at a higher incidence (> 2%) were fatigue (13% vs. 8%), asthenia (10% vs. 7%), proteinuria (7% vs. 0%), hypertension (6% vs. 1%; including hypertension and hypertensive crisis), and hemorrhage (3% vs. 0.3%; including epistaxis, small intestinal hemorrhage, aneurysm ruptured, gastric ulcer hemorrhage, gingival bleeding, hemoptysis, hemorrhage intracranial, large intestinal hemorrhage, respiratory tract hemorrhage, and traumatic hematoma). Adverse reactions are presented in Table 3.

Table 3: Grades 1-5 Adverse Reactions Occurring at Higher Incidence (≥ 5%) of Patients Receiving Bevacizumab vs. Placebo with Interferon-Alfa in Study BO17705

Adverse Reactiona Bevacizumab with Interferon-Alfa
(N = 337)
Placebo with Interferon-Alfa
(N = 304)
Metabolism and nutrition
  Decreased appetite 36% 31%
  Weight loss 20% 15%
General
  Fatigue 33% 27%
Vascular
  Hypertension 28% 9%
Respiratory, thoracic and mediastinal
  Epistaxis 27% 4%
  Dysphonia 5% 0%
Nervous system
  Headache 24% 16%
Gastrointestinal
  Diarrhea 21% 16%
Renal and urinary
  Proteinuria 20% 3%
Musculoskeletal and connective tissue
  Myalgia 19% 14%
  Back pain 12% 6%
a NCI-CTC version 3.

The following adverse reactions were reported at a 5-fold greater incidence in patients receiving bevacizumab with interferon-alfa compared to patients receiving placebo with interferon-alfa and not represented in Table 2: gingival bleeding (13 patients vs. 1 patient); rhinitis (9 vs. 0); blurred vision (8 vs. 0); gingivitis (8 vs. 1); gastroesophageal reflux disease (8 vs. 1); tinnitus (7 vs. 1); tooth abscess (7 vs. 0); mouth ulceration (6 vs. 0); acne (5 vs. 0); deafness (5 vs. 0); gastritis (5 vs. 0); gingival pain (5 vs. 0) and pulmonary embolism (5 vs. 1).

Persistent, Recurrent, Or Metastatic Cervical Cancer

The safety of bevacizumab was evaluated in 218 patients who received at least one dose of bevacizumab in a multicenter study (GOG-0240) in patients with persistent, recurrent, or metastatic cervical cancer [see Clinical Studies]. Patients were randomized (1:1:1:1) to receive paclitaxel and cisplatin with or without bevacizumab (15 mg/kg every 3 weeks), or paclitaxel and topotecan with or without bevacizumab (15 mg/kg every 3 weeks). The demographics of the safety population were similar to the demographics of the efficacy population.

Grades 3−4 adverse reactions occurring at a higher incidence (≥ 2%) in 218 patients receiving bevacizumab with chemotherapy compared to 222 patients receiving chemotherapy alone were abdominal pain (12% vs. 10%), hypertension (11% vs. 0.5%), thrombosis (8% vs. 3%), diarrhea (6% vs. 3%), anal fistula (4% vs. 0%), proctalgia (3% vs. 0%), urinary tract infection (8% vs. 6%), cellulitis (3% vs. 0.5%), fatigue (14% vs. 10%), hypokalemia (7% vs. 4%), hyponatremia (4% vs. 1%), dehydration (4% vs. 0.5%), neutropenia (8% vs. 4%), lymphopenia (6% vs. 3%), back pain (6% vs. 3%), and pelvic pain (6% vs. 1%). Adverse reactions are presented in Table 4.

Table 4: Grades 1-4 Adverse Reactions Occurring at Higher Incidence (≥ 5%) in Patients Receiving Bevacizumab with Chemotherapy vs. Chemotherapy Alone in Study GOG-0240

Adverse Reactiona Bevacizumab with Chemotherapy
(N = 218)
Chemotherapy
(N = 222)
General
  Fatigue 80% 75%
  Peripheral edema 15% 22%
Metabolism and nutrition
  Decreased appetite 34% 26%
  Hyperglycemia 26% 19%
  Hypomagnesemia 24% 15%
  Weight loss 21% 7%
  Hyponatremia 19% 10%
  Hypoalbuminemia 16% 11%
Vascular
  Hypertension 29% 6%
  Thrombosis 10% 3%
Infections
  Urinary tract infection 22% 14%
  Infection 10% 5%
Nervous system
  Headache 22% 13%
  Dysarthria 8% 1%
Psychiatric
  Anxiety 17% 10%
Respiratory, thoracic and mediastinal
  Epistaxis 17% 1%
Renal and urinary
  Increased blood creatinine 16% 10%
  Proteinuria 10% 3%
Gastrointestinal
  Stomatitis 15% 10%
  Proctalgia 6% 1%
  Anal fistula 6% 0.0%
Reproductive system and breast
  Pelvic pain 14% 8%
Hematology
  Neutropenia 12% 6%
  Lymphopenia 12% 5%
a NCI-CTC version 3.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and the specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bevacizumab in the studies described below with the incidence of antibodies in other studies or to other bevacizumab products may be misleading.

In clinical studies for adjuvant treatment of a solid tumor, 0.6% (14/2233) of patients tested positive for treatment-emergent anti-bevacizumab antibodies as detected by an electrochemiluminescent (ECL) based assay. Among these 14 patients, three tested positive for neutralizing antibodies against bevacizumab using an enzyme-linked immunosorbent assay (ELISA). The clinical significance of these anti-bevacizumab antibodies is not known.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of bevacizumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General: Polyserositis

Cardiovascular: Pulmonary hypertension, Mesenteric venous occlusion

Gastrointestinal: Gastrointestinal ulcer, Intestinal necrosis, Anastomotic ulceration

Hemic and lymphatic: Pancytopenia

Hepatobiliary disorders: Gallbladder perforation

Musculoskeletal and Connective Tissue Disorders: Osteonecrosis of the jaw

Renal: Renal thrombotic microangiopathy (manifested as severe proteinuria)

Respiratory: Nasal septum perforation

Read the entire FDA prescribing information for Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion)

© Mvasi Patient Information is supplied by Cerner Multum, Inc. and Mvasi Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors